#CancerMoonshot today will not only be about glioblastoma, but about the horrible DIPG (diffuse intrinsic pontine glioma) occuring in children and young adults.
You know who got their PIP plan approved last year by the MHRA in the UK?
You know who ANNOUNCED a new center of cancer excellence in Sutton in the UK two months ago, 130 miles from Sawston, focusing on DIPG?
You know who donated 2.5 million pounds to the center and that Hugh Adams works for them and have helped NWBO meeting british politicians and he wrote the "Pathway to a Cure" report, where politicians urges MHRA and NICE to get DCVax-L to patients?
SAME DAY MHRA announced this
"This new funding will accelerate the delivery of cutting-edge treatments like cancer vaccines"
One week later the MHRA announced this.
The new Quarterly SEC filing says
"We plan to work on preparations for Phase II trials of DCVax-Direct as resources permit."
You know NWBO already had planned DCVax-Direct trials in 2019 targeting DIPG?
If trading of an over-the-counter (OTC) stock like NWBO (Northwest Biotherapeutics) is halted in Europe, it can significantly affect market makers who have engaged in naked short selling of the stock. Here’s how:
1Liquidity Impact: With the trading halt, the liquidity of NWBO in the European market is essentially frozen. Market makers rely on liquidity to cover their short positions, including naked shorts. Without the ability to trade, they cannot buy shares to close out these positions
2Price Discovery and Arbitrage: Market makers often exploit price differences between different markets. If trading is halted in Europe but continues elsewhere, it can disrupt their ability to engage in arbitrage.
SIO Capital Management, LLC is a global equity market neutral healthcare hedge fund headquartered in New York. Founded by Dr. Michael Castor in 2006, the firm focuses exclusively on the healthcare sector ....
... which includes areas such as biotech, pharmaceuticals, medical devices, insurance, and hospitals. This specialization allows SIO to leverage its deep industry knowledge to identify investment opportunities and mispriced stocks within the complex healthcare landscape.
SIO Capital employs a balanced investment strategy aimed at both capital growth and preservation. Their approach includes rigorous financial analysis and a focus on catalysts that might drive stock performance.
... way for market makers to "cover up" their cumulative short and distort scams and give it a "fair value".
Ranging from 45-65 billion dollars the last couple of years, the number is a placeholder for the destruction of companies, for layoff of employees, for preventing ....
... scientific breakthroughs, working treatments, vaccines and cures getting to people, to patients.
Ultimately it is how Wall Street has agreed to put a fair value on misery, deaths and sorrow.
It is a mechanism to make it possible for SEC and DTCC, to bury "fails to deliver".